Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Chaos (Woodbury, N.Y.)|April 3, 2020
A generic method for constructing n-fold covers of 3D conservative chaotic systemsShijian Cang, Yue Li, Zhijun Kang, et al.Organic Letters|May 21, 2004
Stereoselective synthesis of cis-1,3-disubstituted cyclobutyl kinase inhibitorsChristopher J Helal, Zhijun Kang, John C Lucas, et al.Optics Express|April 4, 2018
High-repetition-rate, high-pulse-energy, and high-beam-quality laser system using an ultraclean closed-type SBS-PCMZhijun Kang, Zhongwei Fan, Yutao Huang, et al.Evidence-Based Complementary and Alternative Medicine : Ecam|June 14, 2016
The Effects of Taoren-Honghua Herb Pair on Pathological Microvessel and Angiogenesis-Associated Signaling Pathway in Mice Model of CCl4-Induced Chronic Liver DiseaseShengyan Xi, Lifeng Yue, Mengmeng Shi, et al.Optics Letters|July 15, 2017
Adaptive aberration correction of a 5 J/6.6 ns/200 Hz solid-state Nd:YAG laserXin Yu, Lizhi Dong, Boheng Lai, et al.Bioorganic & Medicinal Chemistry Letters|October 16, 2004
Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's diseaseChristopher J Helal, Mark A Sanner, Christopher B Cooper, et al.Bioorganic & Medicinal Chemistry Letters|August 25, 2009
Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's diseaseChristopher J Helal, Zhijun Kang, John C Lucas, et al.Journal of Medicinal Chemistry|June 10, 2011
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophreniaChristopher J Helal, Zhijun Kang, Xinjun Hou, et al.Journal of Medicinal Chemistry|October 3, 2012
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitorsMichelle M Claffey, Christopher J Helal, Patrick R Verhoest, et al.Journal of Medicinal Chemistry|October 13, 2021
Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 InhibitorBarbara Czako, Yuting Sun, Timothy McAfoos, et al.Pageof 2